Neuroendocrine tumors of the pancreas

Florian Ehehalt, Hans D. Saeger, C. Schmidt, Robert Grützmann

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

This literature review briefly summarizes the epidemiology, pathophysiology, clinical management, and outcomes of patients with pancreatic neuroendocrine tumors (PNETs) and highlights recent advances in PNET research. PNETs are rare neoplasms, compared with carcinomas arising from pancreatic exocrine tissue. They, like other neuroendocrine tumor types, display variable malignant potential, hormone-related syndromes (functionality), localization, and genetic background. Although tumor origin and molecular pathogenesis remain poorly understood, recently established grading and staging systems facilitate patient risk stratification, and thereby directly impact clinical decision making. Although the optimal clinical management of PNETs involves a multidisciplinary approach, surgery remains the only curative treatment for early-stage disease. Surgery may also have a role in patients with advanced-stage disease, including those with hepatic metastases. Alternative therapeutic approaches applied to PNETs, including chemotherapy, radiofrequency ablation, transarterial chemoembolization, biotherapy, polypeptide radionuclide receptor therapy, antiangiogenic therapy, and selective internal radiotherapy, have failed to demonstrate a long-term survival benefit. Surgery remains the primary therapeutic option for patients with PNETs. Research on PNETs is desperately needed to improve the therapeutic options for patients with this disease.

Original languageEnglish
Pages (from-to)456-467
Number of pages12
JournalOncologist
Volume14
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Neuroendocrine Tumors
Pancreas
Therapeutics
Biological Therapy
Research
Radioisotopes
Neoplasms
Epidemiology
Radiotherapy
Hormones
Neoplasm Metastasis
Drug Therapy
Peptides
Survival
Liver

Keywords

  • Gastrinoma
  • Insulinoma
  • Neuroendocrine
  • Pancreas
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ehehalt, F., Saeger, H. D., Schmidt, C., & Grützmann, R. (2009). Neuroendocrine tumors of the pancreas. Oncologist, 14(5), 456-467. https://doi.org/10.1634/theoncologist.2008-0259

Neuroendocrine tumors of the pancreas. / Ehehalt, Florian; Saeger, Hans D.; Schmidt, C.; Grützmann, Robert.

In: Oncologist, Vol. 14, No. 5, 05.2009, p. 456-467.

Research output: Contribution to journalArticle

Ehehalt, F, Saeger, HD, Schmidt, C & Grützmann, R 2009, 'Neuroendocrine tumors of the pancreas', Oncologist, vol. 14, no. 5, pp. 456-467. https://doi.org/10.1634/theoncologist.2008-0259
Ehehalt, Florian ; Saeger, Hans D. ; Schmidt, C. ; Grützmann, Robert. / Neuroendocrine tumors of the pancreas. In: Oncologist. 2009 ; Vol. 14, No. 5. pp. 456-467.
@article{aac562a88e0e4ba283f0f3fcd3bb77e3,
title = "Neuroendocrine tumors of the pancreas",
abstract = "This literature review briefly summarizes the epidemiology, pathophysiology, clinical management, and outcomes of patients with pancreatic neuroendocrine tumors (PNETs) and highlights recent advances in PNET research. PNETs are rare neoplasms, compared with carcinomas arising from pancreatic exocrine tissue. They, like other neuroendocrine tumor types, display variable malignant potential, hormone-related syndromes (functionality), localization, and genetic background. Although tumor origin and molecular pathogenesis remain poorly understood, recently established grading and staging systems facilitate patient risk stratification, and thereby directly impact clinical decision making. Although the optimal clinical management of PNETs involves a multidisciplinary approach, surgery remains the only curative treatment for early-stage disease. Surgery may also have a role in patients with advanced-stage disease, including those with hepatic metastases. Alternative therapeutic approaches applied to PNETs, including chemotherapy, radiofrequency ablation, transarterial chemoembolization, biotherapy, polypeptide radionuclide receptor therapy, antiangiogenic therapy, and selective internal radiotherapy, have failed to demonstrate a long-term survival benefit. Surgery remains the primary therapeutic option for patients with PNETs. Research on PNETs is desperately needed to improve the therapeutic options for patients with this disease.",
keywords = "Gastrinoma, Insulinoma, Neuroendocrine, Pancreas, Tumor",
author = "Florian Ehehalt and Saeger, {Hans D.} and C. Schmidt and Robert Gr{\"u}tzmann",
year = "2009",
month = "5",
doi = "10.1634/theoncologist.2008-0259",
language = "English",
volume = "14",
pages = "456--467",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Neuroendocrine tumors of the pancreas

AU - Ehehalt, Florian

AU - Saeger, Hans D.

AU - Schmidt, C.

AU - Grützmann, Robert

PY - 2009/5

Y1 - 2009/5

N2 - This literature review briefly summarizes the epidemiology, pathophysiology, clinical management, and outcomes of patients with pancreatic neuroendocrine tumors (PNETs) and highlights recent advances in PNET research. PNETs are rare neoplasms, compared with carcinomas arising from pancreatic exocrine tissue. They, like other neuroendocrine tumor types, display variable malignant potential, hormone-related syndromes (functionality), localization, and genetic background. Although tumor origin and molecular pathogenesis remain poorly understood, recently established grading and staging systems facilitate patient risk stratification, and thereby directly impact clinical decision making. Although the optimal clinical management of PNETs involves a multidisciplinary approach, surgery remains the only curative treatment for early-stage disease. Surgery may also have a role in patients with advanced-stage disease, including those with hepatic metastases. Alternative therapeutic approaches applied to PNETs, including chemotherapy, radiofrequency ablation, transarterial chemoembolization, biotherapy, polypeptide radionuclide receptor therapy, antiangiogenic therapy, and selective internal radiotherapy, have failed to demonstrate a long-term survival benefit. Surgery remains the primary therapeutic option for patients with PNETs. Research on PNETs is desperately needed to improve the therapeutic options for patients with this disease.

AB - This literature review briefly summarizes the epidemiology, pathophysiology, clinical management, and outcomes of patients with pancreatic neuroendocrine tumors (PNETs) and highlights recent advances in PNET research. PNETs are rare neoplasms, compared with carcinomas arising from pancreatic exocrine tissue. They, like other neuroendocrine tumor types, display variable malignant potential, hormone-related syndromes (functionality), localization, and genetic background. Although tumor origin and molecular pathogenesis remain poorly understood, recently established grading and staging systems facilitate patient risk stratification, and thereby directly impact clinical decision making. Although the optimal clinical management of PNETs involves a multidisciplinary approach, surgery remains the only curative treatment for early-stage disease. Surgery may also have a role in patients with advanced-stage disease, including those with hepatic metastases. Alternative therapeutic approaches applied to PNETs, including chemotherapy, radiofrequency ablation, transarterial chemoembolization, biotherapy, polypeptide radionuclide receptor therapy, antiangiogenic therapy, and selective internal radiotherapy, have failed to demonstrate a long-term survival benefit. Surgery remains the primary therapeutic option for patients with PNETs. Research on PNETs is desperately needed to improve the therapeutic options for patients with this disease.

KW - Gastrinoma

KW - Insulinoma

KW - Neuroendocrine

KW - Pancreas

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=66349128030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349128030&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2008-0259

DO - 10.1634/theoncologist.2008-0259

M3 - Article

C2 - 19411317

AN - SCOPUS:66349128030

VL - 14

SP - 456

EP - 467

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -